Eupraxia Pharmaceuticals (NASDAQ:EPRX) Trading Up 1.9% – Time to Buy?

Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX)’s share price was up 1.9% on Thursday . The company traded as high as $3.27 and last traded at $3.24. Approximately 15,739 shares changed hands during mid-day trading, an increase of 86% from the average daily volume of 8,450 shares. The stock had previously closed at $3.18.

Analyst Ratings Changes

A number of analysts have weighed in on EPRX shares. RODMAN&RENSHAW upgraded shares of Eupraxia Pharmaceuticals to a “strong-buy” rating in a research report on Thursday, November 14th. Rodman & Renshaw initiated coverage on shares of Eupraxia Pharmaceuticals in a report on Thursday, November 14th. They set a “buy” rating and a $9.00 price target on the stock.

Eupraxia Pharmaceuticals Stock Up 1.2 %

The business’s 50 day moving average is $3.12 and its two-hundred day moving average is $2.88. The firm has a market cap of $116.83 million and a P/E ratio of -4.56.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Eupraxia Pharmaceuticals stock. Bank of Montreal Can increased its position in shares of Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) by 15.2% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 56,750 shares of the company’s stock after purchasing an additional 7,500 shares during the quarter. Bank of Montreal Can owned approximately 0.16% of Eupraxia Pharmaceuticals worth $178,000 as of its most recent SEC filing.

Eupraxia Pharmaceuticals Company Profile

Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company. It focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Th company’s lead product candidate includes EP-104IAR, for the treatment of pain due to osteoarthritis of the knee.